The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, defined by the International Council for Harmonisation. The study was approved by the institutional review board at each participating site.

Shubham Pant: research support to institution for Elicio, Amal Therapeutics, Janssen, Arcus, Astellas, Biontech, Boehringer Ingelheim, Mirati Therapeutics, Bristol Myers Squibb, 4D Pharma, Framewave, ImmunoMET, Ipsen, Lilly, NGM Pharmaceuticals, Novartis; Pfizer, Xencor, Immuneering, and Zymeworks; and consulting/advisory fees from USWorldmeds, Alligator Bioscience, Boehringer Ingelheim, Novartis, BPGBio, Ipsen, AstraZeneca, Janssen, Jazz Pharmaceuticals, AskGene Pharma, Nihon Medi-Physics Co, Ltd, and Zymeworks. Byoung Chul Cho: research funding from Cyrus, Abbvie, AstraZeneca, Dizal Pharma, Bayer, Blueprint Medicines, Bridgebio Therapeutics, CHA Bundang Medical Center, Champions Oncology, CJ Blossom Park, Dong-A ST, Genexine, GI-Cell, CJ Bioscience, GI-ImmuneOncia, Hanmi, Abion, Illumina, Innovation, Interpark Bio Convergence Corp, Janssen, JINTSbio, Kanaph Therapeutics, LG Chem, Boehringer Ingelheim, Lilly, MOGAM Institute, MSD, Novartis, Nuvalent, Ono, Oscotec, Regeneron, Therapex, Vertical Bio AG, Oncternal, and Yuhan; consulting fees from AstraZeneca, Janssen, BeiGene, Novartis, Boehringer-Ingelheim, CJ, CureLogen, Cyrus Therapeutics, Abion, Eli Lilly, GI-Cell, Guardant, Hanmi, Bristol Myers Squibb, HK Inno-N, Imnewrun Biosciences Inc., Medpacto, MSD, Ono, Onegene Biotechnology, Pfizer, RandBio, Takeda, Blueprint Medicines, and Yuhan; honoraria from Chinese Thoracic Oncology Society, International Association for the Study of Lung Cancer, American Society of Clinical Oncology, European Society of Medical Oncology, Guardant, Pfizer, AstraZeneca, Korean Cancer Study Group, Korean Society of Medical Onoclogy, Korean Society of Thyroid, Head and Neck Surgery, MSD, Novartis, Roche, and Korean Cancer Association; advisory board roles for Cyrus Therapeutics, Bridgebio Therapeutics, Guardant Health, J INTS BIO, Gilead, KANAPH Therapeutic Inc, Oscotec Inc, Amgen, and Therapex; royalties from Crown Bioscience, Bio GmbH, Champions Oncology, PearlRiver, Imagen, and Roche; member of the board of directors for J INTS BIO; founder of DAAN Biotherapeutics; and stock ownership for Cyrus Therapeutics, Gencurix Inc, Interpark Bio Convergence Corp., J INTS BIO, KANAPH Therapeutics, Bridgebio Therapeutics, and TheraCanVac Inc. Christos E. Kyriakopoulos: research support from Bristol Myers Squibb, Merck, AstraZeneca, Gilead Sciences, Pionyr Immunopharma, Incyte Corporation, and Sanofi-Aventis; participation in Advisory Boards for Janssen, AVEO Pharmaceuticals, Exelixis, and Sanofi-Aventis; stock for EPIC Systems Inc. Alexander Spira: honoraria from Bristol Myers Squibb, Amgen, Novartis, Bayer, CytomX Therapeutics, Janssen Oncology, Merck, AstraZeneca/MedImmune, and Takeda; consulting/advisory roles for Incyte,Amgen, Blueprint Medicines, Array Biopharma, AstraZeneca/MedImmune, Black Diamond Therapeutics, Janssen Research & Development; Bristol Myers Squibb, Mersana, Daiichi Sankyo, Sanofi, Gritstone Oncology, Jazz Pharmaceuticals, Lilly, Merck, Mirati Therapeutics, Novartis, Regeneron, and Takeda; research funding from Abbvie, Bristol Myers Squibb, ADCT, Alkermes, Arch Therapeutics, Arrivent Biopharma, Astellas Pharma, AstraZeneca/MedImmune, Ignyta, Astex Pharmaceuticals, Plexxikon,Black Diamond Therapeutics, Gritstone Oncology, Blueprint Medicines, Boehringer Ingelheim, Roche, CytomX Therapeutics, Revolution Medicines, Amgen, Daiichi Sankyo, Incyte, LAM Therapeutics, Loxo, Macrogenics, Medikine, Mersana, Mirati Therapeutics, Synthekine, Janssen Oncology, Nalo Therapeutics, Novartis, Regeneron, Rubius, Scorpion Therapeutics, and Takeda; leadership role for NEXT Oncology (Virginia); and stock ownership for Eli Lilly Nizar Tannir: clinical grants from Exelixis, Bristol Myers Squibb, Nektar Pharmaceuticals, Calithera Biosciences, and Novartis; honoraria for consultancy/advisory roles from Exelixis, AstraZeneca, Eisai, Intellisphere, Merck, Nektar Therapeutics, Bristol Myers Squibb, and Oncorena; and stock or stock options for Biocryst Pharmaceuticals, Merck, Surface Oncology, Amgen, Vanguard Healthcare, Johnson & Johnson/Janssen, and SPDR S&P Pharmaceuticals. Theresa L. Werner: research support to institution for Mersana Therapeutics, Abbvie, GSK-Tesaro, Acrivon, BluePrint Medicines, Clovis Oncology, Genmab, Repare Therapeutics, AstraZeneca, and Roche Genetech; and honoraria for advisory roles from Mersana Therapeutics Xiaohong Yan: employment, stock ownership and support for meeting attendance for Mirati Therapeutics Inc. Saskia Neuteboom: prior employment and stock ownership for Mirati Therapeutics Inc. Richard Chao: employment, stock ownership and support for meeting attendance for Mirati Therapeutics Inc. Sanjay Goel: research support to institution from Mirati Therapeutics Inc.